Letters, Statements & Analysis

AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.

The United States Capitol Building
Letters, Statements & Analysis

AMCP Comments on Enhancing Coverage of Preventive Services Under the Affordable Care Act

The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services, the Department of Labor, and the Department of the Treasure (collectively, the Departments) for the opportunity to provide comments in response to the proposed rule titled “Enhancing Coverage of Preventive Services Under the Affordable Care Act [CMS 9887–P]” published in the Federal Register on October 28, 2024.
Government/Legal Affairs
NYS Capitol
Letters, Statements & Analysis

State Update: New York Releases Major Market Conduct Regulations for Pharmacy Benefit Managers

On November 21, the New York Department of Financial Services (DFS) announced sweeping market conduct regulations for pharmacy benefit managers (PBMs) serving health plans in the state. The DFS rule implements a landmark 2021 bill, S. 3762/A. 1396, which imposed restrictions on PBM contracts with health plans and pharmacies and established consumer protections. This action follows previous DFS rulemaking that created a broad definition of pharmacy benefit management services, required PBMs operating in the state to obtain a license, and established annual reporting requirements.
Government/Legal Affairs
Capitol Hill, U.S. Capitol, IRA Workshop
Letters, Statements & Analysis

AMCP Comments on the 2025 Medicare Physician Fee Schedule

On September 9, AMCP submitted comments praising CMS’s proposal to cover Digital Mental Health Treatment devices (DMHTs) under Medicare Part B. AMCP urges CMS to use its authority to cover all FDA-cleared, prescription only digital health products and develop appropriate coding and payment methodologies to promote adoption of these innovative technologies.
Medicare
Letters, Statements & Analysis

AMCP, Patient and Provider Groups Applaud Supreme Court Ruling on Alliance for Hippocratic Medicine et al. v FDA et al

On June 13, AMCP joined 24 patient and provider organizations in applauding the Supreme Court's unanimous ruling reversing the Fifth Circuit's decision in Alliance for Hippocratic Medicine et al. v FDA et al. AMCP and the undersigned organizations unequivocally support FDA's role in safeguarding patients, which has yielded approval of tens of thousands of crucial medications and devices for generations of Americans.
Legislation & Regulation
Letters, Statements & Analysis

AMCP Expresses Concerns with State Legislation Restricting Managed Care Pharmacists

On May 29, AMCP released the following statement, which expresses concerns about the Illinois General Assembly's Healthcare protection Act (HB 5395). Passed on May 25, the bill restricts managed care pharmacists' ability to manage prescription drug benefits for millions of Illinoisans covered under the state’s Medicaid program, state employee group insurance, and fully insured commercial plans.
Legislation & Regulation
Letters, Statements & Analysis

AMCP Comment Letter on MPPP Model Documents

On Feb. 29, 2024, the Centers for Medicare and Medicaid Services (CMS) issued The Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents. AMCP submitted comments in response to this Model Documents on April 29, 2024.
Legislation & Regulation